Choroidal infarction following photodynamic therapy with verteporfin

Archives of Ophthalmology

Volumn 123, Issue 8, 2005, Pages 1149-1153

  Klais, Christina M ^b   Ober, Michael D ^b   Freund, K Bailey ^b   Ginsburg, Leonard H ^b   Luckie, Alan ^b   Mauget Faÿsse, Martine ^b   Coscas, Gabriel ^b   Gross, Nicole E ^b   Yannuzzi, Lawrence A ^a  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PORPHYRIN;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; EYE PAIN; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; MALE; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHOROID; INFARCTION; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; VASCULARIZATION;

AGED; AGED, 80 AND OVER; CHOROID; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INFARCTION; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; VISUAL ACUITY;

EID: 23844521599     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.8.1149     Document Type: Article

References (12)

1. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report [erratum appears in Arch Ophthalmol. 2000;118:488]. Arch Ophthalmol. 1999;117:1329-1345.
2. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-560.
3. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101: 1953-1961.
4. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003; 110:1517-1525.
5. Kramer M, Miller JW, Michaud N, et al. Lysosomal benzoporphyrin derivative verteporfin in photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427-438.
6. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40:2322-2331.
7. Costa RA, Farah ME, Cardillo JA, Calducci D, Williams GA. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina. 2003;23:159-165.
8. Schmidt-Erfurth U, Laqua H, Schloetzer-Schrehard U, Viestenz A, Naumann GOH. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835-844.
9. Amalric PM. Choroidal vessel occlusive syndromes: clinical aspects. Trans Am Acad Ophthalmol Otolaryngol. 1973;77:291-299.
10. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiologic choroid. Invest Ophthalmol Vis Sci. 2002;43:830-841.
11. Gomer CJ, Rucker N, Murphren AL. Differential cell photosensitivity following porphyrin photodynamic therapy. Cancer Res. 1988;48:4539-4542.
12. Lange N, Ballini JP, Waguires G, van den Bergh H. A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest Ophthalmol Vis Sci. 2001;42:38-46.